Fresenius Kabi launched Fentanyl Citrate Injection, USP in 100 mcg per 2 mL Simplist ready-to-administer prefilled syringes in the U.S., becoming the only 100 mcg per 2 mL presentation available on the market in a manufacturer-prepared prefilled syringe.
 
This is the most recent manufacturer-prepared product available in the company’s ready-to-administer portfolio of Simplist prefilled syringes, designed for efficient medication delivery and ease of use, to help eliminate steps where errors can occur. Fresenius Kabi currently has 14 products in 25 presentations in its Simplist portfolio.
 
Fentanyl citrate is currently listed as in shortage by the U.S. FDA.
 
Simplist Fentanyl Citrate Injection, USP is formulated, filled, and packaged in the U.S. using fully automated state-of-the-art technology. The company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. health systems. 
 
“Fresenius Kabi is pleased to add this presentation of Fentanyl to our portfolio of Simplist prefilled syringes, further demonstrating our commitment to patient safety and combating drug diversion,” said John Ducker, president and CEO of Fresenius Kabi USA. “By offering this critical care product in secure and convenient ready-to-administer packaging, we are helping frontline health care professionals administer this prescription safely and confidently by helping to minimize administration errors and reduce drug waste.”